Floatz logo

Abt-767

Fallopian Tube

AbbVie (prior sponsor, Abbott)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Fallopian Tube cohort.

Asset / SponsorPhaseRating
Enzalutamide
Memorial Sloan Kettering Cancer Center
Phase 2B
Mirvetuximab Soravtansine
University of Alabama at Birmingham
Phase 2CCC
Nivolumab
Memorial Sloan Kettering Cancer Center
Phase 1CCC
Ny-Eso-1 Vaccine
Memorial Sloan Kettering Cancer Center
Phase 1CC
Carboplatin
Memorial Sloan Kettering Cancer Center
Phase 1CC
wt1 vaccine
Memorial Sloan Kettering Cancer Center
Phase 1CC
Ipilimumab
Memorial Sloan Kettering Cancer Center
Phase 1CC

Same molecule, other indications

Abt-767 is also rated in:

primary peritoneal carcinomaDormant
CC
Indicative ·
42 / 100
View asset →
Solid Tumors (e.g. Breast, Ovarian, Prostate, or Pancreatic) and OvarianDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →